Advertisement

Techniques in Coloproctology

, Volume 19, Issue 6, pp 339–345 | Cite as

Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial

  • I. Giannini
  • A. Amato
  • L. Basso
  • N. Tricomi
  • M. Marranci
  • G. Pecorella
  • S. Tafuri
  • D. Pennisi
  • D. F. Altomare
Original Article

Abstract

Background

The role of a mixture of phlebotonics in the treatment of acute hemorrhoid crisis is investigated to test their efficacy.

Methods

One hundred and thirty-four consecutive patients with an acute hemorrhoidal crisis recruited in five colorectal units entered the study. Sixty-six of them were randomized to receive a mixture of diosmin, troxerutin and hesperidin (group A), and 68 a placebo (group B). The main symptoms, the use of oral painkillers and the Bristol scale score were recorded at each scheduled visit and compared using both Student’s t test for independent samples and the ANOVA models for repeated measures. The presence of edema, prolapse and thrombosis were also recorded and compared using the Chi-square test. Furthermore, the trend of proportions during the time of the evaluations was assessed by the Chi-square test for linear trend.

Results

Pain, bleeding and the proportion of patients who reported persistence of edema and thrombosis decreased significantly after 12 days of treatment in group A. After 6 days, the number of paracetamol tablets taken by patients in group A was significantly lower than the amount of flavonoid mixture.

Conclusions

The use of a mixture of diosmin, troxerutin and hesperidin is a safe and effective mean of managing symptoms of acute hemorrhoidal disease. Furthermore, in patients receiving treatment, there was faster control and lower persistence of edema and thrombosis.

Keywords

Hemorrhoidal crisis Flavonoids Anal pain Anal bleeding Anal itching 

Notes

Conflict of interest

Omikron Italia Srl has been involved in the study by generously providing the active drug and placebo to the units, but did not have access to the data either in the recruitment or in the elaboration and interpretation of the data.

References

  1. 1.
    Altomare DF, Giannini I (2013) Pharmacological treatment of hemorrhoids: a narrative review. Expert Opin Pharmacother 14:2343–2349CrossRefPubMedGoogle Scholar
  2. 2.
    Perera N, Liolitsa D, Iype S (2012) Phlebotonics for haemorrhoids. Cochrane Database Syst Rev 8:CD004322PubMedGoogle Scholar
  3. 3.
    Altomare DF, Roveran A, Pecorella G, Gaj F, Stortini E (2006) The treatment of hemorrhoids: guidelines of the Italian society of colorectal surgery. Tech Coloproctol 10:181–186CrossRefPubMedGoogle Scholar
  4. 4.
    Rivadeneira DE, Steele SR, Ternent C et al (2011) Standards practice task force of the american society of colon and rectal surgeons. Practice parameters for the management of hemorrhoids (revised 2010). Dis Colon Rectum 54:1059–1064CrossRefPubMedGoogle Scholar
  5. 5.
    Ho YH, Tan M, Seow-Choen F (2000) Micronized purified flavonoid fraction compared favourably with rubber band ligations and fiber alone in the management of bleeding haemorrhoids: randomized controlled trial. Dis Colon Rectum 43:66–69CrossRefPubMedGoogle Scholar
  6. 6.
    Khubchandani IT (2001) Randomized clinical trial of micronized flavonoids in the early control of bleeding for acute internal haemorrhoids. Tech Coloproctol 5:57–58PubMedGoogle Scholar
  7. 7.
    Labrid C (1994) Pharmacologic properties of Daflon 500 mg. Angiology 45:524–530PubMedGoogle Scholar
  8. 8.
    Labrid C (1995) A lymphatic function of Daflon 500 mg. Int Angiol 14:36–38PubMedGoogle Scholar
  9. 9.
    Struckmann JR, Nicolaides AN (1994) Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology 45:419–428CrossRefPubMedGoogle Scholar
  10. 10.
    Bartoli M (2013) Efficacia Farmacologica di diversi flebotonici sulla risposta contrattile alla noradrenalina di safene umane isolate. Il Continuum del paziente vascolare 1:2–3Google Scholar
  11. 11.
    Fortini C, Morelli C, Fiorelli V (2010) Effetto biologico di una formulazione a base di diosmina, esperidina, troxerutina (Triade) sulle permeabilità dell’endotelio vasale umano. Il Continuum del paziente vascolare 1:12–16Google Scholar
  12. 12.
    Lohsiriwat V (2012) Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol 18:2009–2017PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Belcaro G, Rosaria Cesarone M, Ledda A et al (2008) O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology 59(Suppl 1):7S–13SCrossRefPubMedGoogle Scholar
  14. 14.
    Cesarone MR, Belcaro G, Pellegrini L et al (2006) Venoruton verus Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 57:131–138CrossRefPubMedGoogle Scholar
  15. 15.
    Danielsson G, Jungbeck C, Peterson K, Norgren L (2002) A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 23:73–76CrossRefPubMedGoogle Scholar
  16. 16.
    Jantet G (2000) RELIEF study: first consolidated European data. Reflux assessment and quality of life improvement with micronized flavonoids. Angiology 51:31–37CrossRefPubMedGoogle Scholar
  17. 17.
    Jantet G (2002) Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized flavonoids. Angiology 53:245–256CrossRefPubMedGoogle Scholar
  18. 18.
    Stuard S, Cesarone MR, Belcaro G et al (2008) Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: safety aspects. Int J Angiol 17:143–148PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Alonso-Coello P, Zhou Q, Martinez-Zapata MJ et al (2006) Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg 93:909–920CrossRefPubMedGoogle Scholar
  20. 20.
    La Torre F, Nicolai AP (2004) Clinical use of micronized purified flavonoid fraction for treatment of symptoms after hemorrhoidectomy: results of a randomized, controlled, clinical trial. Dis Colon Rectum 47:704–710CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia Srl 2015

Authors and Affiliations

  • I. Giannini
    • 1
  • A. Amato
    • 2
  • L. Basso
    • 3
  • N. Tricomi
    • 4
  • M. Marranci
    • 5
  • G. Pecorella
    • 6
  • S. Tafuri
    • 7
  • D. Pennisi
    • 6
  • D. F. Altomare
    • 1
  1. 1.General Surgery and Liver Transplantation Unit, Department of Emergency and Organ Transplantation“A. Moro” UniversityBariItaly
  2. 2.Department of ColoproctologySanremo HospitalSanremoItaly
  3. 3.Department of Surgery “P.Valdoni”Policlinico Umberto I° “Sapienza” UniversityRomeItaly
  4. 4.Coloproctology Unit“Casa di Cura Candela”PalermoItaly
  5. 5.Department of Surgery“Casa di Cura Villa Fiorita”PratoItaly
  6. 6.Department of Surgery, Policlinico Vittorio EmanueleUniversity of CataniaCataniaItaly
  7. 7.Department of Biomedical Science and Human Oncology“A. Moro” UniversityBariItaly

Personalised recommendations